About

Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.

The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).

The tumour plasma cell clone proliferation induces high levels concentration of Monoclonal protein (also called M-Protein) which is the best tumour markers of the disease.

2nd
most common Blood Cancer.
In 20%
of cases, the disease develops without symptoms.

Diagnosis

Serum and urine protein electrophoresis and their immunological characterisation are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.

Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for abnormalities protein detection(3).

Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.

Sebia’s Expertise

Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patient by offering a full range of solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratories sizes. Sebia solutions offer serum and urine proteins electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping), measurement of FLC* and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.

* Under Product Registration approval